UY33824A - ?moduladores del receptor del glucagón?. - Google Patents
?moduladores del receptor del glucagón?.Info
- Publication number
- UY33824A UY33824A UY0001033824A UY33824A UY33824A UY 33824 A UY33824 A UY 33824A UY 0001033824 A UY0001033824 A UY 0001033824A UY 33824 A UY33824 A UY 33824A UY 33824 A UY33824 A UY 33824A
- Authority
- UY
- Uruguay
- Prior art keywords
- glucagon
- formula
- compounds
- receiver modulators
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D241/34—(Amino-pyrazine carbonamido) guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo en la que R1, R2, R3, A1, A2,A3, A4, L, B1, B2, B3 y B4 son como se definen en el presente documento. Se ha descubierto que los compuestos de Fórmula I actúan como antagonistas o agonistas inversos del glucagón. En consecuencia, los compuestos de Fórmula I y las composiciones farmacéuticas de los mismos son útiles para el tratamiento de enfermedades, trastornos o afecciones mediadas por el glucagón.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426600P | 2010-12-23 | 2010-12-23 | |
US201161562008P | 2011-11-21 | 2011-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33824A true UY33824A (es) | 2012-07-31 |
Family
ID=45464650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033824A UY33824A (es) | 2010-12-23 | 2011-12-21 | ?moduladores del receptor del glucagón?. |
Country Status (17)
Country | Link |
---|---|
US (4) | US8809342B2 (es) |
EP (1) | EP2655331A1 (es) |
JP (1) | JP5694561B2 (es) |
KR (1) | KR101506829B1 (es) |
CN (1) | CN103261165B (es) |
AR (1) | AR084579A1 (es) |
AU (1) | AU2011346670B2 (es) |
BR (1) | BR112013016033A2 (es) |
CA (1) | CA2822017C (es) |
MX (1) | MX2013006768A (es) |
NZ (1) | NZ611529A (es) |
RU (1) | RU2013127611A (es) |
SG (1) | SG191040A1 (es) |
TW (1) | TWI429630B (es) |
UY (1) | UY33824A (es) |
WO (1) | WO2012085745A1 (es) |
ZA (1) | ZA201303950B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
CA2822017C (en) * | 2010-12-23 | 2015-04-07 | Pfizer Inc. | Glucagon receptor modulators |
EP2832725A4 (en) | 2012-03-29 | 2015-11-25 | Takeda Pharmaceutical | AROMATIC RING CONNECTION |
WO2014172191A1 (en) | 2013-04-15 | 2014-10-23 | E. I. Du Pont De Nemours And Company | Fungicidal carboxamides |
PT3057969T (pt) | 2013-10-17 | 2018-07-11 | Blueprint Medicines Corp | Composições úteis para tratar distúrbios relacionados com kit |
MX2022011025A (es) * | 2020-03-06 | 2022-10-07 | Alphala Co Ltd | Procesos para producir compuestos de amida, y su forma cristalina y de sal. |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320825A (en) | 1991-05-01 | 1994-06-14 | Trustees Of The University Of Pennsylvania | Serotonin reuptake inhibitors for S.P.E.C.T. imaging |
WO1994014427A2 (en) | 1992-12-23 | 1994-07-07 | Zymogenetics, Inc. | Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation |
ES2141197T3 (es) | 1993-03-19 | 2000-03-16 | Merck & Co Inc | Derivados del acido fenoxifenilacetico. |
GB9408185D0 (en) | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
DE4426346A1 (de) | 1994-07-25 | 1996-02-01 | Basf Ag | Herbizide Pyrazinderivate |
GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
AU3642795A (en) | 1994-09-27 | 1996-04-19 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
US5837719A (en) | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
AU702887B2 (en) | 1995-10-31 | 1999-03-11 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
AU730295B2 (en) | 1996-11-20 | 2001-03-01 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
US5880139A (en) | 1996-11-20 | 1999-03-09 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
NZ335992A (en) | 1996-12-05 | 2001-09-28 | Amgen Inc | Substituted pyrimidinone and pyridone compounds and methods of use |
JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
CA2274464C (en) | 1996-12-11 | 2007-01-02 | Basf Aktiengesellschaft | Ketobenzamides as calpain inhibitors |
JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
WO1999001423A1 (en) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
CN1284945A (zh) | 1997-12-19 | 2001-02-21 | 安姆根有限公司 | 取代的吡啶和哒嗪化合物及其药物用途 |
YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
PT1177176E (pt) | 1999-04-28 | 2006-08-31 | Aventis Pharma Gmbh | Derivados de acidos triarilicos como ligandos de receptores ppar. |
ES2250128T3 (es) | 1999-05-17 | 2006-04-16 | Novo Nordisk A/S | Antagonistas/agonistas inversos de glucagon. |
JP2004501897A (ja) | 2000-06-23 | 2004-01-22 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン拮抗薬/逆作用薬 |
US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
EP1345891A1 (en) | 2000-11-17 | 2003-09-24 | Novo Nordisk A/S | Glucagon antagonist/inverse agonist |
GEP20053710B (en) | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
EP1463715A1 (en) | 2001-12-03 | 2004-10-06 | Novo Nordisk A/S | Novel glucagon antagonists |
AU2002349299A1 (en) | 2001-12-03 | 2003-06-17 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
WO2003051357A1 (en) | 2001-12-19 | 2003-06-26 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
WO2003053938A1 (en) | 2001-12-20 | 2003-07-03 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
UA84390C2 (ru) | 2001-12-21 | 2008-10-27 | Ново Нордиск А/Я | Производные амидов как активаторы глюкокиназы |
TWI262917B (en) | 2002-02-01 | 2006-10-01 | Dainippon Sumitomo Pharma Co | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same |
WO2003080545A2 (en) | 2002-03-20 | 2003-10-02 | Metabolex, Inc. | Substituted phenylacetic acids |
AU2003226927A1 (en) | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
AU2003233780A1 (en) | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
JP2006502175A (ja) | 2002-09-12 | 2006-01-19 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び関連疾患を治療する方法 |
US7196106B2 (en) | 2002-11-05 | 2007-03-27 | Merck & Co., Inc | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
US20040097557A1 (en) | 2002-11-13 | 2004-05-20 | Duffy Joseph L. | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
WO2004050039A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
AU2003291959A1 (en) | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Novel glucagon antagonists |
US20040209928A1 (en) | 2002-12-30 | 2004-10-21 | Ravi Kurukulasuriya | Glucagon receptor antagonists/inverse agonists |
US7151114B2 (en) | 2003-01-09 | 2006-12-19 | Boehringer Ingelheim International Gmbh | Use of substituted 2-phenylbenzimidazoles as medicaments |
DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
WO2004063147A1 (en) | 2003-01-10 | 2004-07-29 | Novo Nordisk A/S | Salts and solvates of glucagon antagonists |
AU2004210127B2 (en) | 2003-01-27 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
US20040248937A1 (en) | 2003-04-14 | 2004-12-09 | The Institute For Pharmaceutical Discovery Llc | Substituted phenylalkanoic acids for the treatment of diabetes |
US7138529B2 (en) | 2003-04-16 | 2006-11-21 | Hoffmann-La Roche Inc. | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
BRPI0409916A (pt) | 2003-04-30 | 2006-04-25 | Inst For Pharm Discovery Inc | ácidos carboxìlicos substituìdos com fenila |
EP1626717A4 (en) | 2003-05-09 | 2009-09-09 | Merck & Co Inc | BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS |
US7355049B2 (en) | 2003-06-24 | 2008-04-08 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator |
JP4412098B2 (ja) | 2003-07-31 | 2010-02-10 | Jfeスチール株式会社 | 溶接熱影響部靭性に優れた低降伏比高強度鋼板及びその製造方法 |
WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
WO2005058845A2 (en) | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
WO2005065680A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
CN1950374A (zh) | 2004-05-25 | 2007-04-18 | 辉瑞产品公司 | 四氮杂苯并[e]甘菊环衍生物及其类似物 |
US7989457B2 (en) * | 2004-05-28 | 2011-08-02 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
PT1756064E (pt) | 2004-06-04 | 2008-07-22 | Merck & Co Inc | Derivados de pirazole, composições contendo tais compostos e métodos de utilização |
AU2005254950B2 (en) * | 2004-06-14 | 2010-08-19 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
AU2005272043B2 (en) | 2004-07-07 | 2010-07-29 | Merck Sharp & Dohme Corp. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
US7625938B2 (en) | 2004-07-22 | 2009-12-01 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
DE102004051188A1 (de) | 2004-10-21 | 2006-04-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cyanothiophene, deren Herstellung und deren Verwendung als Arzneimittel |
US7524870B2 (en) | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
US20060122236A1 (en) * | 2004-12-06 | 2006-06-08 | Wood Michael R | Substituted biaryl-carboxylate derivatives |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
ATE445609T1 (de) | 2005-02-11 | 2009-10-15 | Lilly Co Eli | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen |
AU2006227435A1 (en) | 2005-03-21 | 2006-09-28 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives |
WO2006104826A2 (en) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
JP2009502923A (ja) | 2005-07-26 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾールを合成するための方法 |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
PL1951272T3 (pl) | 2005-10-06 | 2016-12-30 | Zastosowanie lactobacillus do leczenia infekcji wirusowych | |
TW200745031A (en) | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
US7928113B2 (en) | 2005-11-14 | 2011-04-19 | University Of Southern California | Integrin-binding small molecules |
PT1951658E (pt) * | 2005-11-17 | 2012-11-12 | Lilly Co Eli | Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas |
DK1951661T3 (da) | 2005-11-17 | 2012-09-03 | Lilly Co Eli | Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser deraf |
PT1951659E (pt) | 2005-11-18 | 2010-09-10 | Lilly Co Eli | Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas |
US8691856B2 (en) * | 2005-11-22 | 2014-04-08 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
DK1957484T3 (da) | 2005-11-23 | 2010-05-10 | Lilly Co Eli | Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser |
CA2633010A1 (en) | 2005-12-19 | 2007-06-28 | Methylgene Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
TW200806611A (en) | 2006-02-09 | 2008-02-01 | Daiichi Seiyaku Co | Novel amidopropionic acid derivatives and medicine containing the same |
EP2001472A2 (en) | 2006-03-23 | 2008-12-17 | Merck and Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
AU2007254329A1 (en) | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
KR20180099916A (ko) | 2007-02-09 | 2018-09-05 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
JP2009040702A (ja) | 2007-08-07 | 2009-02-26 | Daiichi Sankyo Co Ltd | 新規アミドプロピオン酸誘導体を含有する医薬組成物 |
WO2009035558A1 (en) | 2007-09-12 | 2009-03-19 | Merck & Co., Inc. | Process for the production of a crystalline glucagon receptor antagonist compound |
US8309580B2 (en) * | 2007-11-01 | 2012-11-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
PT2231701E (pt) | 2007-12-11 | 2012-05-28 | Cadila Healthcare Ltd | Peptidomiméticos com actividades antagonistas do glucagon e agonistas do glp-1 |
EA019752B1 (ru) | 2008-03-05 | 2014-06-30 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое амидное соединение и его применение для лечения/профилактики диабета |
AU2009221722B2 (en) | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
CA2724294A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
CN104803891B (zh) | 2008-08-13 | 2017-10-20 | 症变治疗公司 | 胰高血糖素拮抗剂 |
WO2010019828A1 (en) * | 2008-08-13 | 2010-02-18 | Metabasis Therapeutics, Inc. | Glucagon receptor antagonists |
US8436015B2 (en) | 2008-09-15 | 2013-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US8361959B2 (en) | 2008-10-03 | 2013-01-29 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
WO2010071750A1 (en) | 2008-12-19 | 2010-06-24 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
WO2010080971A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Crystalline polymorphic forms of an antidiabetic compound |
US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US8809579B2 (en) | 2009-02-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2010098994A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
TWI491393B (zh) | 2009-05-14 | 2015-07-11 | Sumitomo Dainippon Pharma Co Ltd | 3- (4-aminophenyl) -2-furancarboxylic acid derivatives and pharmaceutically acceptable salts thereof |
US8470773B2 (en) | 2009-06-12 | 2013-06-25 | Merck Sharp & Dohme Corp. | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | 3−(4−置換アルキル−フェニル)−2−フランカルボン酸誘導体およびその薬学的に許容される塩 |
WO2011027849A1 (ja) | 2009-09-04 | 2011-03-10 | 武田薬品工業株式会社 | 複素環化合物 |
EP2480077B1 (en) | 2009-09-22 | 2015-02-18 | Merck Sharp & Dohme Corp. | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
US20130012434A1 (en) | 2010-03-25 | 2013-01-10 | Wong Michael K | Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
JP2013523642A (ja) | 2010-03-26 | 2013-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン誘導体、組成物およびそれらの使用方法 |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
CA2822017C (en) * | 2010-12-23 | 2015-04-07 | Pfizer Inc. | Glucagon receptor modulators |
-
2011
- 2011-12-09 CA CA2822017A patent/CA2822017C/en not_active Expired - Fee Related
- 2011-12-09 JP JP2013545549A patent/JP5694561B2/ja not_active Expired - Fee Related
- 2011-12-09 AU AU2011346670A patent/AU2011346670B2/en not_active Ceased
- 2011-12-09 NZ NZ611529A patent/NZ611529A/en not_active IP Right Cessation
- 2011-12-09 MX MX2013006768A patent/MX2013006768A/es active IP Right Grant
- 2011-12-09 KR KR1020137016206A patent/KR101506829B1/ko not_active IP Right Cessation
- 2011-12-09 CN CN201180061388.0A patent/CN103261165B/zh not_active Expired - Fee Related
- 2011-12-09 SG SG2013043732A patent/SG191040A1/en unknown
- 2011-12-09 BR BR112013016033A patent/BR112013016033A2/pt not_active IP Right Cessation
- 2011-12-09 RU RU2013127611/04A patent/RU2013127611A/ru not_active Application Discontinuation
- 2011-12-09 EP EP11805952.6A patent/EP2655331A1/en not_active Withdrawn
- 2011-12-09 WO PCT/IB2011/055588 patent/WO2012085745A1/en active Application Filing
- 2011-12-21 UY UY0001033824A patent/UY33824A/es not_active Application Discontinuation
- 2011-12-22 AR ARP110104917A patent/AR084579A1/es unknown
- 2011-12-22 TW TW100148111A patent/TWI429630B/zh not_active IP Right Cessation
- 2011-12-22 US US13/334,202 patent/US8809342B2/en not_active Expired - Fee Related
-
2013
- 2013-05-30 ZA ZA2013/03950A patent/ZA201303950B/en unknown
-
2014
- 2014-07-18 US US14/334,718 patent/US8933104B2/en not_active Expired - Fee Related
- 2014-12-05 US US14/561,879 patent/US9056834B2/en not_active Expired - Fee Related
-
2015
- 2015-06-05 US US14/731,632 patent/US20150266861A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2014500306A (ja) | 2014-01-09 |
KR101506829B1 (ko) | 2015-03-30 |
US20120165343A1 (en) | 2012-06-28 |
JP5694561B2 (ja) | 2015-04-01 |
CA2822017C (en) | 2015-04-07 |
AR084579A1 (es) | 2013-05-29 |
CA2822017A1 (en) | 2012-06-28 |
KR20130087588A (ko) | 2013-08-06 |
AU2011346670B2 (en) | 2015-05-07 |
US20150266861A1 (en) | 2015-09-24 |
BR112013016033A2 (pt) | 2018-06-05 |
US20140329862A1 (en) | 2014-11-06 |
SG191040A1 (en) | 2013-08-30 |
ZA201303950B (en) | 2014-07-30 |
EP2655331A1 (en) | 2013-10-30 |
RU2013127611A (ru) | 2015-01-27 |
US20150094338A1 (en) | 2015-04-02 |
US9056834B2 (en) | 2015-06-16 |
WO2012085745A1 (en) | 2012-06-28 |
TW201302706A (zh) | 2013-01-16 |
MX2013006768A (es) | 2013-07-22 |
US8933104B2 (en) | 2015-01-13 |
AU2011346670A1 (en) | 2013-07-25 |
CN103261165A (zh) | 2013-08-21 |
US8809342B2 (en) | 2014-08-19 |
CN103261165B (zh) | 2015-08-26 |
NZ611529A (en) | 2015-06-26 |
TWI429630B (zh) | 2014-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012871A (es) | Moduladores del receptor de glucagón | |
UY39630A (es) | Inhibidores de bromodominios | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
UY33824A (es) | ?moduladores del receptor del glucagón?. | |
CR20150474A (es) | Inhibidores de bromodominios tetracíclicos | |
CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
CO6410295A2 (es) | Derivados de indol como antagonistas del receptor crth2 | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
MX2015012158A (es) | Inhibidores de bomodominio tetraciclicos fusionados. | |
UY35177A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
MX2014012374A (es) | Compuestos organicos. | |
ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
EA201692433A1 (ru) | Соединения ppar для применения при лечении фиброзных заболеваний | |
CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
CO6300937A2 (es) | Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200217 |
|
109 | Application deemed to be withdrawn |
Effective date: 20210618 |